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PURPOSE. Dysfunction of the renin-angiotensin system (RAS) contributes to pathogenesis of
diabetic retinopathy (DR). Yet RAS blockers have only limited beneficial effects on
progression of DR in clinical trials. The natriuretic peptide system offsets RAS, so that
enhancing the activity of this system on top of RAS blockade might be beneficial. Neprilysin
has an important role in the degradation of natriuretic peptides. Therefore, we hypothesize
that dual angiotensin receptor-neprilysin inhibition (ARNI) may outperform angiotensin
receptor blocker (ARB) in protection against DR. We tested this hypothesis in streptozotocin-
induced diabetic transgenic (mRen2)27 rats.
METHODS. Adult male diabetic (mRen2)27 rats were followed for 5 or 12 weeks. Treatment
with vehicle, irbesartan (ARB), or ARB combined with the neprilysin inhibitor thiorphan
(irbesartanþthiorphan [ARNI]) occurred during the final 3 weeks. Retinal cell death, gliosis,
and capillary loss were evaluated. Real-time polymerase chain reaction (RT-PCR) analyses
were performed to quantify the retinal level of inflammatory cell markers.
RESULTS. Both ARB- and ARNI-treated groups showed similarly reduced retinal apoptotic cell
death, gliosis, and capillary loss compared to the vehicle-treated group in the 5-week study.
Treatment with ARNI reduced the expression of inflammatory markers more than ARB
treatment in the 5-week study. In the 12-week study, ARNI treatment showed significantly
more reduction in apoptotic cell death (51% vs. 25% reduction), and capillary loss (68% vs.
43% reduction) than ARB treatment.
CONCLUSIONS. Treatment with ARNI provides better protection against DR in diabetic
(mRen2)27 transgenic rats, compared to ARB alone. This approach may be a promising
treatment option for patients with DR.
Keywords: diabetes, diabetic retinopathy, renin-angiotensin system, AT1 receptor, angiotensin
receptor blocker, irbesartan, neprilysin, thiorphan
Diabetes affects approximately 387 million people world-wide. Diabetic retinopathy (DR) is the most common
complication of diabetes and the major cause of vision loss in
middle-aged subjects.1 The development of DR is strongly
associated with the development of diabetic kidney disease,
suggesting that the same pathogenic pathway underlies these
complications.2 The renal renin-angiotensin system (RAS) is
upregulated in diabetes, evidenced by increased tissue levels of
angiotensin II, the main effector peptide of the RAS. Elevated
levels of angiotensin II contribute to pathogenic processes,
such as inflammation, vascular remodeling, and oxidative
stress,3 that are associated with various renal and cardiovascu-
lar disorders, like heart failure, hypertension, diabetes, and
other metabolic disorders.4,5 Diabetic retinopathy is associated
with activation of the local RAS in the eye, evidenced by an
increase in retinal angiotensin II levels.6,7 Blockers of the RAS,
like angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin II type 1 receptor blockers (ARBs) provide
protection against the progression of cardiovascular disorders,
diabetic kidney disease, and diabetic retinopathy.8 Still, these
drugs are unable to completely reverse or halt the progression
of these complications. The natriuretic peptide system
regulates diuresis, natriuresis, and vasodilatory functions of
the cardiovascular system, and it offsets the RAS, so that
enhancing the activity of this system on top of RAS blockade
might be beneficial.9 Neprilysin (NEP) is a critical enzyme for
the breakdown of a variety of substrates, including vasodilators,
vasoconstrictors, and natriuretic peptides. The individual use of
NEP inhibitors, however, did not prove to be very beneficial for
the treatment of heart failure and other cardiovascular
disorders, mainly due to its broad action on different
vasodilators and vasoconstrictors. When a NEP inhibitor is
combined with an angiotensin receptor blocker (the combina-
tion is referred to as ‘‘ARNI’’), the balance shifts to the positive,
blood pressure–lowering side. Indeed, ARNI has been shown to
be more effective than RAS blockade alone in (1) reducing
blood pressure,10 (2) improving morbidity and mortality in
heart failure,11–13 and (3) improving surrogate cardiovascular
outcomes in diabetic patients.14,15 In diabetic, hypertensive
rats, we have shown previously that ARNI lowers proteinuria
and the development of focal segmental glomerulosclerosis,
common features of diabetic kidney disease, more than ARB
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alone. This effect may even be independent of blood
pressure.16 Therefore, we hypothesize that dual inhibition also
may provide better protection against DR, compared to ARB
alone. We tested this hypothesis in transgenic (mRen2)27
(Ren2) rats made diabetic with streptozotocin (STZ). This is a
well-known model of diabetic retinopathy.17–20 We made use
of the ARB irbesartan and the NEP inhibitor thiorphan.16,21
METHODS
Animal Studies
Heterozygous male Ren2 rats (age 10 weeks, weight 300–500
g) were obtained by crossing homozygous Ren2 and Sprague-
Dawley (SD) rats. Only male Ren2 rats were used for this
particular study as the females of this transgenic model develop
a much milder phenotype.22 Studies were performed in
accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research and under the regulation
and permission of the Erasmus MC Animal Care Committee.
Diabetes mellitus was induced by administering streptozotocin
(55 mg/kg intraperitoneal [IP]; Merck Millipore, Amsterdam,
The Netherlands), and diabetic animals were studied for 5 or
12 weeks. In the 5-week group, heart rate and BP were
measured by radiotelemetry transmitters, implanted 2 weeks
before induction of diabetes.23 Rats were checked daily for
nonfasting blood glucose and b-ketone levels until day 3 after
STZ injection, and thereafter once weekly or every other week
(5- and 12-week groups, respectively; Precision Xceed; Abbott,
Zwolle, The Netherlands). Only rats with glucose >15 mmol/L
were considered diabetic; they received 2 to 4 U insulin per
day (Levemir; Novo Nordisk, Bagsvaerd, Denmark). Rats in
both groups were treated during the final 3 weeks of the study
(i.e., during weeks 2–5 or 9–12) with vehicle (saline containing
0.2% dimethylsulfoxide [DMSO]), the ARB irbesartan (15 mg/
kg.day; Sanofi-Aventis, Chilly-Mazarin, France), or the ARNI
irbesartanþthiorphan (0.1 mg/kg.day diluted in DMSO; Sigma-
Aldrich Corp., St. Louis, MO, USA) making use of osmotic
minipumps (2ML4; ALZET, Cupertino, CA, USA). After 3 weeks
of treatment, animals were killed by IP pentobarbital injection
(200–240 mg/kg). Renal, cardiac, and vascular data on these
animals have been reported previously.16 Each experimental
group had 7 to 12 rats. In addition, eyes also were obtained
from 8 age-matched untreated nondiabetic Sprague-Dawley rats
that were used as wild-type controls. Eyes were harvested at
the end of the 5-week or 12-week study, one eye from each
animal was fixed in 4% paraformaldehyde (PFA) for histologic
analysis and the other eye was snap frozen in liquid nitrogen
for protein and gene expression analysis.
NEP Activity Assay
Frozen eyes from each experimental group were dissected to
isolate retinal tissue that then were homogenized by sonication
in NEP assay buffer (100 mM Tris-HCl pH 7.5, 50 mM NaCl, 10
lM ZnCl2). Neprilysin activity assay was performed using 5 lg
of retinal protein in black 96-well opaque plates with the
fluorogenic peptide substrate Mca-RPPGFSAFK(Dnp)-OH (En-
zo Life Science, Farmingdale, NY, USA) added at a final
concentration of 20 lM. The enzymatic reaction was done at
378C in the presence and absence of the NEP inhibitor
thiorphan at 2 lM concentration. The enzymatic reaction was
recorded in a SpectraMax M3 fluorescence microplate reader
(Molecular Devices, Sunnyvale, CA, USA) for 1 hour with
excitation at 320 nm and emission at 405 nm as described
previously.24,25 All measurements were performed in duplicate
and the data represent the means of three assay results.
Immunofluorescence
Eyes fixed in 4% PFA were processed for paraffin embedding.
Paraffin sections (4 lm thick) were cut and mounted on
superfrost slides. Sections were deparaffinized in xylene and
decreasing concentration of alcohol. This was followed by an
antigen retrieval step where the slides were boiled for 20
minutes in sodium citrate buffer, pH 6.0. The sections then
were incubated in blocking solution (5% BSAþ 0.3 % Triton X-
100 in PBS) for 1 hour. This was followed by incubation with
different primary antibodies: rabbit anti-glial fibrillary acidic
protein (GFAP 1:1000, Sigma-Aldrich Corp., St. Louis, MO,
USA), rabbit anti-Iba-1 (1:200; DAKO, Carpinteria, CA, USA),
mouse anti-Brn3a (1:200; Millipore, Billerica, MA, USA) diluted
in the same blocking solution (overnight at 48C). The sections
then were incubated with the appropriate secondary antibod-
ies conjugated to Alexa 488 or 594 (Molecular Probes/
Invitrogen, Eugene, OR, USA) for 1 hour at RT. Sections were
washed in PBS containing the nuclear counterstain DAPI (40,6
diamidino-2-phenylindole), and mounted in Dako mounting
media (DAKO). For TUNEL staining the In Situ Cell Death
Detection Kit, TMR red (Roche Applied Science, Indianapolis,
IN, USA) was used on paraffin sections in accordance with the
manufacturer’s instructions. The images were captured on a
Keyence confocal microscope (KEYENCE Corporation, Itasca,
TABLE 1. Real-Time PCR Primers
Gene
Accession
Number Sequences
ICAM-1 NM_012967 50 CCCCACCTACATACATTCCTAC 30
50 ACATTTTCTCCCAGGCATTC 30
TNF-a NM_012675 CCTTATCTACTCCCAGGTTCTC
TTTCTCCTGGTATGAAATGGC
VEGF NM_031836 TGC ACC CAC GAC AGA AGG GGA
TCA CCG CCT TGG CTT GTC ACA T
MCP-1 NM_031550 GCAGCAGGTGTCCCAAAGAAGCT
AGAAGTGCTTGAGGTGGTTGTGGAA
TABLE 2. Main Characteristics of DM Ren2 Rats That Were Treated for 3 Weeks With Vehicle, ARB or ARNI
5 Wks. DM 12 Wks. DM
Parameter Vehicle ARB ARNI Vehicle ARB ARNI
Body weight, g 448 613 452 6 16 450 6 11 448 6 9 482 6 20 430 6 23
Blood glucose, mmol/L 27 6 0.6 27 6 0.7 27 6 0.5 27 6 0.3 25 6 1.9 26 6 0.7
Baseline mean arterial pressure, mm Hg 157 6 10 160 6 10 154 6 10 – – –
Change in mean arterial pressure, mm Hg 9.5 6 4.3 45.0 6 7.8*† 47.7 6 7.9*† – – –
Treatment was started either 2 weeks (‘‘5 weeks DM’’) or 9 weeks (‘‘12 weeks DM’’) after the induction of DM. Data are meanþ SEM of 7 to 12 rats.
* P < 0.05 versus baseline.
† P < 0.05 versus vehicle.
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IL, USA) or on a spinning disc confocal microscope (Ultra
VIEW Vox; PerkinElmer, Waltham, MA, USA) using a320,340,
and/or360 objective lens and were prepared for presentation
using Adobe Photoshop (Adobe Systems, Inc., San Jose, CA,
USA). For GFAP quantification, digital images captured in
Adobe Photoshop were adjusted similarly for brightness and
contrast. Images were thresholded in ImageJ (National
Institutes of Health [NIH], Bethesda, MD, USA) and the
fluorescence intensity and area were quantified using its
Measure module. For cell counts and GFAP expression, each
quantification was performed on at least 5 sections from at
least 6 animals (i.e., at least 30 sections each experimental
group).
Western Blot Analysis
To quantify the level of GFAP expression in the different
experimental groups, retinal tissues were collected in cold
RIPA buffer (Sigma-Aldrich Corp.) supplemented with protease
inhibitors and were homogenized by sonication. Homogenized
tissues were centrifuged at 12,000g for 15 minutes at 48C and
the supernatant was collected. The protein concentration was
detected by Bio-Rad Protein Assay kit (Bio-Rad Life Sciences,
Hercules, CA, USA). Protein samples (20 lg) were loaded and
separated on 10% gels for 1 hour at 120 V in Tris-glycine buffer
and electrophoretically transferred onto polyvinylidene di-
fluoride membrane. Immunodetection was performed on blots
blocked in fluorescence-blocking buffer for 1 hour (Rockland
Immunochemicals, Inc., Gilbertsville, PA, USA) and then
incubated with primary (rabbit anti- GFAP; 1:2000; Sigma-
Aldrich Corp.), and secondary (goat anti-rabbit IR Dye 800;
1:5000; Rockland Immunochemicals, Inc.) antibodies. b-Actin
antibody (mouse anti-b-actin; 1:5000; Sigma-Aldrich Corp.)
immunoblotting was used as a loading control. Immunoblots
were visualized and quantified by using a Li-Cor odyssey
infrared imager after normalizing it to b-Actin (Odyssey; Li-Cor,
Lincoln, NE, USA).
Trypsin Digest Preparations of Retinal Vasculature
Trypsin digest preparations of retinal vasculature were made as
described previously.26 Briefly, the retinas were dissected from
the 4% PFA fixed eye cups, washed in water for an hour, and
digested in 3% trypsin for 2 to 3 hours at RT. The tissue then
was transferred into water and the network of vessels was
freed from adherent retinal tissue by gentle shaking and
manipulation under a dissection microscope. The vessels then
were mounted on clean slides and allowed to dry and stained
with periodic acid Schiff-hematoxylin and eosin (PAS-H&E; Gill
No.3; Sigma-Aldrich Corp.). After the tissue was stained and
washed in water, it was dehydrated and mounted (Permount
mounting media; Fisher Scientific, Pittsburgh, PA). The
prepared retinal vessels were photographed by a Zeiss
microscope equipped with a high-resolution digital camera
(AxioCam, MRC5, Zeiss Axionvert 200; Carl Zeiss Meditec,
Jena, Germany) using 320 and 340 objective lenses, 6 to 8
representative nonoverlapping fields from each quadrant of the
retina were imaged. Acellular capillaries were counted from
images for each retina and expressed as the number of acellular
vessels per square millimeter.
Real-Time PCR Analysis
Total RNA was isolated from frozen rat retinal samples using
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to
manufacturer’s instruction. Reverse transcription was per-
formed using Enhanced Avian HS RT-PCR kit (Sigma-Aldrich
Corp.) following manufacturer’s instructions. Real-time PCR
was done on a real-time thermal cycler (iCycler; Bio-Rad Life
Sciences) using iQTM Syber Green Supermix (Bio-Rad Life
Sciences). The threshold cycle number (Ct) for real-time PCR
was set by the cycler software. Optimal primer concentration
for PCR was determined separately for each primer pair. Each
reaction was run in duplicate or in triplicate, and reaction
tubes with target primers and those with actin primers always
were included in the same PCR run. The expression levels of
the different genes were established based on the Ct compared
to control housekeeping gene b-actin in each sample (amount
of target ¼ 2DDCt) and presented as fold change. The rat
specific primers used in this experiment are listed in Table 1.
RESULTS
Induction of Diabetes Mellitus and General
Physiologic Characteristics
Ren2 rats developed hypertension but had a normal blood
glucose level, identical to that in SD rats as reported
previously.16,17 Streptozotocin-induced diabetes mellitus in-
creased blood glucose levels (Table 2). Treatment with ARB or
ARNI did not affect the glucose level nor the body weight, but
significantly reduced mean arterial blood pressure (Table 2).
Streptozotocin-induced diabetic retinopathy in Ren2 rats is
FIGURE 1. Neprilysin activity assay in STZ-induced diabetic Ren2 rat
retinas and control retinas obtained from non-diabetic SD rats. (A)
Relative fluorescence intensity and (B) Accumulative fluorescence
intensity as a measure of NEP activity level using protein samples
extracted from Ren-2 rat retinas show an increase in NEP activity in
STZ-induced diabetic Ren2 rat retinal samples when compared to
control nondiabetic SD rat retinal samples. Angiotensin receptor
blocker and ARNI treatment resulted in reduction in the level of NEP
activity. All measurements were performed in duplicate and the
experiment was repeated at least twice with similar results. *P < 0.05
compared to control. #P < 0.05 compared to vehicle; N¼ 3 per group.
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associated with a corresponding increase in the activity of NEP
enzyme (Fig. 1). Treatment with ARB and ARNI reduced the
level of NEP activity in the 5- and 12-week studies, with ARNI
having a stronger effect than ARB in the 5-week study but appear
to have almost a similar effect in the 12-week study (Fig. 1B).
ARNI Reduced Gliosis More Strongly Than ARB
After 12 Weeks of Diabetes
Immunostaining for GFAP, an astrocyte-specific marker, was
done in each group to evaluate the level of gliosis. In a normal
healthy retina, GFAP expression is confined to the astrocytes at
the inner limiting membrane. However, under pathologic
conditions, like DR, GFAP expression is elevated and also
observed in the Mu¨ller cell processes that extend across the
retina from the inner limiting membrane to the outer limiting
membrane. In a previous study in nondiabetic Ren2 rats, we
observed that retinal GFAP expression is slightly elevated
versus age-matched SD controls in astrocytes.17 In diabetic
Ren2 rats, retinal GFAP expression was greatly elevated, and
seen along the Mu¨ller cell processes (Fig. 2). The longer the
duration of diabetes, the higher the level of GFAP expression
that was observed. Angiotensin receptor blocker– and ARNI-
treated groups showed similarly reduced retinal gliosis
compared to the vehicle-treated group in the 5-week study.
In the 12-week study, the ARNI-treated group showed a marked
reduction in the level of GFAP expression when compared to
the vehicle and the ARB-treated group (Figs. 2A–D). Retinal
sections from each group also were immunostained for Iba-1,
which is a marker for activated microglial cells. In the 5-week
study, ARB- and ARNI-treated groups displayed almost the same
number of Iba-1–positive cells as the vehicle-treated group. In
the 12-week study, the total number of Iba-1–positive cells was
significantly (P < 0.01) reduced in the ARNI-treated group
when compared to the vehicle and ARB-treated groups (Figs.
3A, 3B). Angiotensin receptor blocker treatment alone also
reduced the total number of Iba-1–positive cells versus vehicle.
ARNI Is More Effective Than ARB in Reducing
Apoptotic Cell Death After 12 Weeks of Diabetes
Paraffin sections from each group were processed for TUNEL
labeling to evaluate retinal degeneration. Compared to the
nondiabetic control group the diabetic vehicle-treated groups
showed a marked increase in the number of cells undergoing
apoptotic cell death in the 5-week (2.4-fold increase) and 12-
week (2.8-fold increase) study. The ARB- and ARNI-treated
groups showed similarly reduced apoptotic cell death com-
FIGURE 2. Immunofluorescence and Western blot detection of GFAP expression in retina. (A) GFAP immunostaining in 5-week (top) and 12-week
(bottom) diabetic rats, treated for 3 weeks with vehicle, ARB, or ARNI. Scale bar: 20 lm. ONL, outer nuclear layer; INL, inner nuclear layer; IPL,
inner plexiform layer. (B) Quantification of GFAP immunofluorescence in representative rat retinal sections from each experimental group,
including nondiabetic (control) rats. n¼8 per group (5–6 sections/animal). (C) GFAP Western blot showing a reduction in GFAP expression in ARB-
and ARNI-treated groups when compared to the vehicle group. Upper: GFAP and bottom: b-actin. (D) Quantification of GFAP band intensity in
Western blot normalized to b-actin. n¼ 4. ns, not significant, *P < 0.05, **P < 0.001.
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pared to the vehicle-treated group in the 5-week study. In the
12-week study, the ARNI-treated group showed a marked
reduction (51%) in the number of apoptotic cell deaths when
compared to the vehicle-treated group, while the ARB-treated
group showed only a 25% reduction versus vehicle (Figs. 4A,
4B). Immunostaining for Brn3a which is a specific retinal
ganglion cell (RGC) marker was used to quantify the number of
RGC in retinal sections from each experimental group as
another measure for retinal neurodegeneration. Number of
Brn3aþ cells in the control group was significantly higher
when compared to the 5-week and 12-week vehicle-treated
group. In the 5-week study, ARB and ARNI treatment resulted
in a statistically significant increase in number of Brn3aþ RGC
cells when compared to the vehicle-treated group. In the 12-
week study ARNI-treated group showed an increase in number
of Brn3aþ RGC cells while the ARB and vehicle-treated group
showed a reduced Brn3aþ RGC cells (Fig. 4C).
ARNI Reduced Capillary Loss More Strongly Than
ARB After 12 Weeks of Diabetes
We have reported previously that the Ren2 rat retina shows an
increased loss of capillaries when compared to age-matched SD
rats.17 Streptozotocin-induced diabetes in Ren2 rats further
exacerbated this loss. Angiotensin receptor blocker- and ARNI-
treated groups showed a similar reduction in the number of
acellular capillaries compared to vehicle-treated group in the 5-
week study. In the 12-week study, ARNI treatment showed
significantly more reduction in capillary loss (68% vs. 43%
reduction) than ARB treatment (Fig. 5).
ARNI Decreased Expression Levels of
Inflammatory Markers More Strongly Than ARB
After Both 5 and 12 Weeks of Diabetes
Real-time RT-PCR was used to evaluate the expression level
of inflammatory cytokines and angiogenic factors in the
FIGURE 3. Immunofluorescence detection of activated microglial cells
in retina. (A) Quantification of Iba-1 positive cells in the different
experimental groups, including nondiabetic control rats. (B) Repre-
sentative images of Iba-1 Immunostaining in rat retinal sections from
different groups. Scale bar: 20 lm. *P < 0.05. n ¼ 6 per group (5–6
sections/animal).
FIGURE 4. In situ cell death detection by TUNEL assay in retina. (A)
Quantification of TUNEL-positive cells in the different experimental
groups, including nondiabetic control rats. (B) Representative images
of TUNEL immunostaining in rat retinal sections from different groups.
(C) Quantification of Brn3a-positive cells in different experimental
groups, including nondiabetic control rats. Scale bar: 20 lm. *P <
0.05, ** P < 0.001, n ¼ 6 per group (5–6 sections/animal).
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retina from each experimental group. In the 5-week study
and the 12-week study ARB and ARNI treatment significantly
reduced the mRNA levels of TNF-a, intercellular adhesion
molecule-1 (ICAM-1), VEGF, and monocyte chemoattractant
protein-1 (MCP-1) when compared to the vehicle treated
groups (Fig. 6).
DISCUSSION
The present study first showed that STZ-induced diabetes in
Ren2 rats resulted in increased levels of NEP activity, capillary
loss, inflammatory cytokine expression, gliosis, and neuronal
apoptotic cell death in the retina, which all are indicators of
FIGURE 5. Histologic detection of acellular capillaries in retina. (A) Representative images of trypsin-digested retinal vascular preparations from
different groups of the 12-week study. (B) Quantification of acellular capillaries in the different experimental groups. *P < 0.01, n¼ 4 per group.
FIGURE 6. Real-time RT-PCR detection of inflammatory cytokines in retina. Real-time PCR analysis of mRNA extracted from rat retinas of different
experimental groups for inflammatory marker genes: TNF-a, VEGF, ICAM-1, and MCP-1. Y-axis shows the fold change in the gene expression level
normalized to b-actin. *P < 0.01, n¼ 4 per group.
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DR. This is consistent with our earlier work in this model.17
Secondly, these symptoms exacerbated after a longer duration
of diabetes; the increase in capillary loss, inflammatory
cytokine expression, gliosis, and apoptotic cell death were all
significantly worsened after 12 weeks of diabetes compared to
5 weeks of diabetes. This could have important clinical
significance in terms of developing potential therapeutics, as
DR, a progressive retinal neurovascular disorder, is strongly
associated with prolonged duration of diabetes in patients.1
Thirdly, this study provides strong evidence that, in the 12-
week study, ARNI is much more effective than ARB alone in
ameliorating the retinal neurovascular dysfunctions observed
in diabetic Ren2 rats, while the two treatments were equally
effective at 5 weeks. Thus, the use of a NEP inhibitor in
addition to an ARB seems to provide additional benefits effects
on the retinal neurovascular system, making ARNI a promising
therapeutic approach in the treatment of DR. To what degree
the beneficial effects of ARNI in the eye at 12 weeks occurred
independently of blood pressure still must be investigated.
Nevertheless, given the identical blood pressure lowering
effects of ARNI and ARB at 5 weeks, at this stage there is no
reason to believe that this would be entirely different at 12
weeks.
A large body of evidence suggests that a deficiency in the
natriuretic peptide system in addition to a hyperactive RAS is
associated with various renal and cardiovascular diseases like
heart failure, hypertension, and metabolic syndromes.27–29
Natriuretic peptides are a family of hormones that help
maintain sodium and fluid balance. This system comprises
three structurally similar peptides: atrial natriuretic peptide
(ANP), B-type natriuretic peptide (BNP) and C-type natriuretic
peptide (CNP).30 All three peptides have cardiorenal protective
properties. Natriuretic peptides, in addition to having potent
natriuretic, diuretic, and vasodilator properties, also lower
sympathetic drive, and have antiproliferative and antihyper-
trophic effects.31 These actions are mediated by the binding of
ANP and BNP to the type A receptor, which is coupled to
guanylyl cyclase. C-type natriuretic peptide is found mostly in
the central nervous system, kidneys, and vascular endothelial
cells; it has antithrombotic and antifibrotic effects and binds to
the type B receptor. The activation of both these receptors
increases the expression of the second messenger cGMP,
which mediates most of the natriuretic peptide mechanisms of
action. The natriuretic peptides are cleared from circulation via
receptor-mediated internalization (involving the natriuretic
peptide clearance receptor) and/or degradation by extracellu-
lar proteases, like NEP.32,33 Natriuretic peptides and their
receptors are expressed and functional in the rodent and
human eyes in lens epithelial cells, vitreous, neural retina, and
RPE.34–36 Although their role in the retina is not yet clear,
induction of diabetes in rats causes downregulation of retinal
ANP expression. The activity level of NEP in the vitreous of
patients with proliferative DR is increased compared to control
patients.36 Additionally, in our present study we showed that
STZ-induced DR in Ren2 rats results in increased level of NEP
activity, which can be significantly reduced by ARB and ARNI
treatment. Moreover, it has been shown that ANP and CNP can
suppress endothelial and RPE leakage, prevent choroidal
neovascularization,37,38 and reverse advanced glycation end-
product-induced retinal blood-barrier dysfunction in RPE.35 All
these processes precede the development of DR. Thus,
inhibiting NEP and increasing the level of natriuretic peptides
in the retina could be beneficial in the treatment of DR.
Increasing the levels of natriuretic peptide by NEP
inhibitors has been investigated as a therapeutic approach for
treatment of hypertension and heart failure.39,40 However, the
use of NEP inhibitors individually was not very beneficial, due
to its broad effects on a variety of substrates other than
natriuretic peptides.31 Indeed, NEP is critical for the process-
ing and catabolism of vasoactive peptides and peptides
involved in diuresis, natriuresis, and blood pressure regulation,
like angiotensin II, bradykinin, substance P, adrenomedullin,
glucagon, vasoactive intestinal peptide, and endothelin-1.30
Therefore, in recent studies NEP inhibitors were used in
combination with other cardiovascular agents, such as ACEi
and ARBs, to at least counteract their potentiating effects on
angiotensin II.31,41,42 The combination of a NEP inhibitor and
an ACEi was not useful because of a high incidence of
angioedema, due to increased bradykinin levels43,44 related to
the fact that NEP and ACE are the main enzymatic pathways for
the breakdown of bradykinin. An alternative combination is
that of an ARB and a NEP inhibitor (ARNI). Angiotensin
receptor blockers do not disrupt bradykinin metabolism, and
patients on ARNI did not seem to develop angioedema.41,42
This combination could be additionally beneficial because
blockade of the angiotensin II type 1 receptor by ARB
facilitates the binding of angiotensin II to the angiotensin II
type 2 receptor that elicits several favorable actions. Clinical
studies using ARNI for the treatment of heart failure and
hypertension have shown much stronger favorable results
when compared to ARB, without any extra associated negative
side effects.10,12,42,45
Possible chronic adverse effects of NEP inhibitors on the
eye have not specifically been assessed yet. Neprilysin has a
possible neuroprotective effect as it brings about degradation
of the amyloid b peptide.36,46 Elevated levels of amyloid b
peptide in the brain is associated with cognitive impairment,
and extracellular deposition leads to the development of
Alzheimer’s disease. Elevated levels of amyloid b peptide in the
eye have been found in different progressive retinal neurode-
generative disorders, such as age-related macular degenera-
tion.47–49 Hence, further studies must be done to better
understand the long-term effects of NEP inhibitors on the eye
before they can be applied for the treatment of DR.
Nevertheless, the beneficial effect that ARNI has over ARB on
retinal neurovascular symptoms in diabetic Ren2 rats suggest
that this treatment holds promise as a novel potential
therapeutic strategy for treatment of patients with DR.
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